CNTB
Connect Biopharma Holdings Limited
NASDAQ · Healthcare · Biotechnology · CN
$1.84
−4.66%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 3.7M | 64.0K | 26.0M | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | 3.7M | 64.0K | 26.0M | — | — |
| Operating Expenses | |||||
| R&D Expense | 42.6M | 37.8M | 29.3M | 53.0M | 96.6M |
| SG&A Expense | 17.1M | 20.3M | 19.2M | 16.1M | 20.8M |
| General & Admin Expense | 17.1M | 20.3M | 19.2M | 16.1M | 20.8M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 19.8M | — | — | — | 1.9M |
| Total Operating Expenses | 79.5M | 58.1M | 48.5M | 69.1M | 119.3M |
| Cost and Expenses | 79.5M | 58.1M | 48.5M | 69.1M | 119.3M |
| Operating Income (EBIT) | (75.8M) | (58.1M) | (22.5M) | (69.1M) | (119.3M) |
| Non-Operating | |||||
| Interest Income | 6.6M | 2.3M | 4.5M | 5.2K | 1.6M |
| Interest Expense | — | — | — | — | 21.0K |
| Net Interest Income | 6.9M | 2.3M | 4.5M | 5.2K | 1.5M |
| Other Non-Op Income/Expense | 2.5M | 2.8M | 7.0M | 7.1M | 1.5M |
| Non-Operating Income (excl Interest) | (1.8M) | (2.8M) | (7.0M) | (7.1M) | (1.5M) |
| EBT (Pre-Tax Income) | (73.3M) | (55.3M) | (15.4M) | (62.0M) | (117.8M) |
| Income Tax Expense | 296.0K | 197.0K | 223.0K | 120.0K | 298.0K |
| Bottom Line | |||||
| Net Income | (73.6M) | (55.5M) | (15.6M) | (62.1M) | (118.1M) |
| Earnings from Cont. Ops | (73.6M) | (55.5M) | (15.6M) | (62.1M) | (118.1M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (73.6M) | (55.5M) | (15.6M) | (62.1M) | (118.1M) |
| Per Share | |||||
| Basic EPS | ($1.53) | ($1.00) | ($0.28) | ($1.08) | ($14.50) |
| Diluted EPS | ($1.53) | ($1.00) | ($0.28) | ($1.08) | ($14.50) |
| Revenue Per Share | $0.06 | $0.00 | $0.47 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 62.9M | 55.7M | 55.2M | 55.1M | 55.0M |
| Diluted Shares Outstanding | 62.9M | 55.7M | 55.2M | 55.1M | 55.0M |
| Profitability Metrics | |||||
| EBITDA | (73.1M) | (54.6M) | (14.7M) | (61.3M) | (116.7M) |
| D&A | 835.0K | 704.0K | 660.0K | 720.0K | 1.0M |
| EBIT | (73.9M) | (55.3M) | (15.4M) | (62.0M) | (117.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026